/
We are a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension ( PAH ) and pulmonary hypertension associated with interstitial lung disease ( PH-ILD ). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, for…
The business is unprofitable at the operating level (-32.45% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1031.2% YoY with margins expanding 834.2pp.
Negative free cash flow of -$40M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$288M
▲ +1031.2% YoY
Net Income (TTM)
$22M
▲ +46.3% YoY
Op. Margin
15.81%
▲ +834.2pp YoY
ROIC
68.23%
▲ +79.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$41M
▲ +59.3% YoY
Op. Cash Flow (TTM)
$48M
▲ +61.8% YoY
Net Debt
-$216M
Net Cash Position
Cash & Equiv.
$223M
5Y CAGR: +192.5%
Continue Research